[O5] Oral Session 5　乳腺
【E】

[O5-5] Trastuzumab Deruxtecan in Patients with HER2+ Metastatic BC: Updated Survival Results from a Ph2 Study, DESTINY-Breast01

^○山下 年成¹, Modi Shanu², Krop Ian³, Park Yeon Hee⁴, Kim Sung-Bae⁵, 田村 研治⁶, Andre Fabrice⁷, 岩田 広治⁸, 伊藤 良則⁹, 鶴谷 純司¹⁰, Sohn Joohyuk¹¹, Lee Caleb¹², Liu Yali¹², Cathcart Jillian¹², Singh Jasmeet¹², Saura Cristina¹³ (1.神奈川県立がんセンター, 2.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3.Dana-Farber Cancer Institute, Boston, MA, USA, 4.Samsung Medical Center, Seoul, South Korea, 5.Asan Medical Center, Seoul, South Korea, 6.島根大学医学部附属病院, 7.Gustave Roussy, Villejuif, France, 8.愛知県がんセンター, 9.日本医科大学, 10.昭和大学, 11.Yonsei Cancer Center, Seoul, South Korea, 12.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 13.Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain)